Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
238.00
-0.66 (-0.28%)
May 11, 2026, 12:12 PM EDT - Market open
Ascendis Pharma Analyst Ratings
Total Analysts
14
Consensus Rating
Strong Buy
Price Target
$283.79
Upside
+19.24%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $342 → $345 | Buy | Maintains | $342 → $345 | +44.96% | May 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $330 → $326 | Buy | Maintains | $330 → $326 | +36.97% | May 8, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $262 → $292 | Strong Buy | Maintains | $262 → $292 | +22.69% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $273 | Buy | Reiterates | $273 | +14.71% | Apr 9, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $252 → $290 | Strong Buy | Initiates | $252 → $290 | +21.85% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $250 → $275 | Buy | Maintains | $250 → $275 | +15.55% | Mar 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $246 → $262 | Buy | Maintains | $246 → $262 | +10.08% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $240 → $273 | Buy | Maintains | $240 → $273 | +14.71% | Feb 12, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $246 → $260 | Strong Buy | Maintains | $246 → $260 | +9.24% | Jan 30, 2026 |
| Barclays | Barclays | Buy Initiates $342 | Buy | Initiates | $342 | +43.70% | Jan 28, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $245 → $250 | Buy | Maintains | $245 → $250 | +5.04% | Jan 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $322 → $330 | Buy | Maintains | $322 → $330 | +38.66% | Jan 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $297 → $322 | Buy | Maintains | $297 → $322 | +35.29% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Reiterates $325 | Strong Buy | Reiterates | $325 | +36.55% | Jan 7, 2026 |
| Stifel | Stifel | Strong Buy Maintains $254 → $256 | Strong Buy | Maintains | $254 → $256 | +7.56% | Dec 11, 2025 |
| Wedbush | Wedbush | Buy Reiterates $220 | Buy | Reiterates | $220 | -7.56% | Nov 18, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.